| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 40,750 | 40,970 | 15.04. | |
| 40,740 | 40,940 | 15.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 42,150 | 2.000 | |||
| 42,000 | 538 | |||
| 41,920 | 35 | |||
| 41,900 | 541 | |||
| 41,780 | 100 | |||
| 41,700 | 500 | |||
| 41,440 | 2.500 | |||
| 41,300 | 34 | |||
| 40,970 | 2.088 | |||
| 40,950 | 200 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/bayn.htm [/URL] | ||||
| 2.288 | 40,750 | |||
| 400 | 40,200 | |||
| 2.370 | 40,000 | |||
| 40 | 39,900 | |||
| 832 | 39,600 | |||
| 1.750 | 39,500 | |||
| 428 | 39,000 | |||
| 100 | 38,810 | |||
| 5 | 38,800 | |||
| 355 | 38,750 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 8.568 | 0,996 | 8.536 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:29:50 | 40,790 | 338 |
| 17:29:50 | 40,790 | 137 |
| 17:29:45 | 40,770 | 52 |
| 17:29:32 | 40,780 | 30 |
| 17:29:29 | 40,770 | 355 |
| 17:29:29 | 40,770 | 96 |
| 17:29:01 | 40,790 | 345 |
| 17:29:01 | 40,790 | 122 |
| 17:29:00 | 40,800 | 591 |
| 17:29:00 | 40,810 | 1 |
| 17:29:00 | 40,810 | 103 |
| 17:29:00 | 40,800 | 3 |
| 17:28:49 | 40,810 | 70 |
| 17:28:45 | 40,820 | 600 |
| 17:28:45 | 40,820 | 178 |
| 17:28:45 | 40,820 | 127 |
| 17:28:43 | 40,830 | 740 |
| 17:28:42 | 40,830 | 164 |
| 17:28:42 | 40,830 | 474 |
| 17:28:42 | 40,830 | 126 |
| Tagesumsatz Xetra | +0,130 +0,32 % | 2,7 Mio. |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BAYER Aktie jetzt für 0€ handeln | |||||
| Mi | Basta: KI-Hustentest empfiehlt Bayer-Vital-Produkte | 36 | turi2 | ||
| Mi | EXKLUSIV zu Bayer: Analysten sehen massives Kurspotenzial - Handeln Sie, bevor es zu spät ist | Hebelschein-Spekulant | |||
| Mi | BAYER AG zündet Kursrakete - DAX-Tagessieger mit Ansage! | 122 | Maximilian Berger | ||
| Di | Opportunities from the Agricultural Transition: Bayer, Sumitomo, and MustGrow Biologics | 23 | The Market Herald Canada | ||
| Di | Chancen dank Agrarwende: Bayer, Sumitomo und MustGrow Biologics | 1.287 | inv3st.de | Die konventionelle Landwirtschaft muss umdenken: Chemische Pestizide sollen reduziert und durch biologische Alternativen ersetzt werden. Strenge Vorschriften wie die Farm-to-Fork-Strategie der Europäischen... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| Mi | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Mi | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| Mi | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| Mi | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen |